Detecting liver toxicity early using exosomal signatures in 3D liver tissues
Early Toxicity Detection Technologies via Exosomal Signatures in 3D Hepatic Tissues
This study is working on new ways to spot liver damage from medications early on by looking at tiny particles called exosomes, using special 3D liver models to make sure the results are as close to real life as possible, which could help keep you safer when new drugs are developed.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10675730 on NIH RePORTER |
What this research studies
This research focuses on developing innovative technologies to detect liver toxicity caused by drugs at an early stage. By analyzing exosomes, which are tiny vesicles that carry genetic material and signaling molecules, the study aims to create a reliable method for predicting adverse drug reactions. The approach involves using 3D hepatic tissue models to better mimic human liver responses, allowing researchers to correlate in vitro findings with real-life conditions. This could lead to improved safety assessments for new medications before they reach the market.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are prescribed medications known to potentially cause liver toxicity.
Not a fit: Patients who are not taking medications that affect liver function or those with pre-existing liver conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the number of drugs withdrawn from the market due to liver toxicity, enhancing patient safety and treatment options.
How similar studies have performed: Previous research has shown promise in using exosomal analysis for detecting drug-induced liver injuries, indicating that this approach may be viable.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Usta, Osman Berk — Massachusetts General Hospital
- Study coordinator: Usta, Osman Berk
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.